keyword
https://read.qxmd.com/read/30171370/a-randomized-double-blind-trial-of-comparative-efficacy-and-safety-of-avonex-and-cinnovex-for-treatment-of-relapsing-remitting-multiple-sclerosis
#21
RANDOMIZED CONTROLLED TRIAL
Hossein Pakdaman, Mehdi Abbasi, Koroush Gharagozli, Farzad Ashrafi, Hosein Delavar Kasmaei, Ali Amini Harandi
BACKGROUND AND AIM: Interferon beta is currently the first line treatment of relapsing-remitting multiple sclerosis (RRMS). Different formulations of interferon beta are available. Avonex and CinnoVex are two interferon beta-1a being prescribed by neurologists in Iran. The aim of this study was to compare the four and half year outcome of Avonex and CinnoVex in patients with RRMS. METHODS: A total 186 of patients with definite RRMS diagnosis were followed for four and half years...
December 2018: Neurological Sciences
https://read.qxmd.com/read/30138155/factors-affecting-the-adherence-to-disease-modifying-therapy-in-patients-with-multiple-sclerosis
#22
JOURNAL ARTICLE
Öznur Erbay, Öznur Usta Yeşilbalkan, Nur Yüceyar
BACKGROUND: Adherence to medication treatment in patients with multiple sclerosis (MS) is important to increase its effectiveness, reduce patient disability, prevent attacks, and increase the quality of life. AIM: This study investigated factors that influence adherence to disease-modifying therapy in patients with MS. METHODS: This descriptive study was conducted with 198 patients with MS who met the inclusion criteria and agreed to participate between July 2016 and February 2017...
October 2018: Journal of Neuroscience Nursing: Journal of the American Association of Neuroscience Nurses
https://read.qxmd.com/read/29960044/interaction-of-pegylated-interferon-beta-with-antibodies-to-recombinant-interferon-beta
#23
JOURNAL ARTICLE
Francesca Gilli, Adrianna L De La Torre, Darlene B Royce, Andrew R Pachner
Because PEGylated molecules exhibit different physicochemical properties from those of the parent molecules, PEGylated interferonβ-1a (pegIFNβ-1a) may be able to be used with retained bioactivity in Multiple Sclerosis (MS) patients who have previously developed neutralizing antibodies (NABs) to recombinant interferonβ (rIFNβ). Hence, the objective of the present study was to test whether pegIFNβ-1a is less antigenic for NABs in vitro than rIFNβ. Two in vitro assays were used to quantitate NABs in 115 sera obtained from MS patients included in the INSIGHT study: the cytopathic effect (CPE) assay, and the MxA protein induction assay...
September 2018: International Immunopharmacology
https://read.qxmd.com/read/29943693/phase-iii-sunbeam-and-radiance-part-b-trials-for-ozanimod-in-relapsing-multiple-sclerosis-demonstrate-superiority-versus-interferon-%C3%AE-1a-avonex-%C3%A2-in-reducing-annualized-relapse-rates-and-mri-brain-lesions
#24
Volker Koscielny
Biography: Volker Koscielny, MD, is the Vice President, Global Medical Affairs, for Inflammation and Immunology at Celgene. Volker trained as a doctor in his native Germany and worked for several pharmaceutical companies prior to joining Celgene in January 2015.
June 2018: Neurodegenerative Disease Management
https://read.qxmd.com/read/29627038/combining-clinical-and-magnetic-resonance-imaging-markers-enhances-prediction-of-12-year-employment-status-in-multiple-sclerosis-patients
#25
JOURNAL ARTICLE
Lucie Kadrnozkova, Manuela Vaneckova, Lukas Sobisek, Barbora Benova, Karolina Kucerova, Jiri Motyl, Michaela Andelova, Klara Novotna, Jana Lizrova Preiningerova, Jan Krasensky, Eva Havrdova, Dana Horakova, Tomas Uher
BACKGROUND: Multiple sclerosis (MS) is frequently diagnosed in the most productive years of adulthood and is often associated with worsening employment status. However, reliable predictors of employment status change are lacking. OBJECTIVE: To identify early clinical and brain magnetic resonance imaging (MRI) markers of employment status worsening in MS patients at 12-year follow-up. METHODS: A total of 145 patients with early relapsing-remitting MS from the original Avonex-Steroids-Azathioprine (ASA) study were included in this prospective, longitudinal, observational cohort study...
May 15, 2018: Journal of the Neurological Sciences
https://read.qxmd.com/read/29229891/cost-effectiveness-of-oral-agents-in-relapsing-remitting-multiple-sclerosis-compared-to-interferon-based-therapy-in-saudi-arabia
#26
COMPARATIVE STUDY
Mai F Alsaqa'aby, Varun Vaidya, Noura Khreis, Thamer Al Khairallah, Ahmed H Al-Jedai
BACKGROUND: Promising clinical and humanistic outcomes are associated with the use of new oral agents in the treatment of relapsing-remitting multiple sclerosis (RRMS). This is the first cost-effectiveness study comparing these medications in Saudi Arabia. OBJECTIVES: We aimed to compare the cost-effectiveness of fingolimod, teriflunomide, dimethyl fumarate, and interferon (IFN)-b1a products (Avonex and Rebif) as first-line therapies in the treatment of patients with RRMS from a Saudi payer perspective...
November 2017: Annals of Saudi Medicine
https://read.qxmd.com/read/29178444/alemtuzumab-versus-interferon-beta-1a-for-relapsing-remitting-multiple-sclerosis
#27
REVIEW
Jian Zhang, Shengliang Shi, Yueling Zhang, Jiefeng Luo, Yousheng Xiao, Lian Meng, Xiaobo Yang
BACKGROUND: Alemtuzumab is a humanised monoclonal antibody that alters the circulating lymphocyte pool, causing prolonged lymphopenia, thus remoulding the immune repertoire that accompanies homeostatic lymphocyte reconstitution. It has been proved more effective than interferon (IFN) 1a for the treatment of relapsing-remitting multiple sclerosis (RRMS). OBJECTIVES: To compare the efficacy, tolerability and safety of alemtuzumab versus interferon beta 1a in the treatment of people with RRMS to prevent disease activity...
November 27, 2017: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/29049356/treatment-satisfaction-with-injectable-disease-modifying-therapies-in-patients-with-relapsing-remitting-multiple-sclerosis-the-stick-study
#28
JOURNAL ARTICLE
Oscar Fernández, Eduardo Duran, Teresa Ayuso, Luis Hernández, Inmaculada Bonaventura, Mireia Forner
BACKGROUND: Treatment satisfaction in patients with relapsing-remitting multiple sclerosis (RRMS) may impact adherence and thus clinical outcomes. The objective of this study was to measure the satisfaction of patients with RRMS with injectable disease-modifying therapies (DMTs) and to evaluate the factors associated with treatment satisfaction. MATERIAL AND METHODS: In this observational retrospective study conducted in the neurology departments of 35 hospitals throughout Spain, demographic data, disease characteristics, and information on treatment with injectable DMTs were collected at a single scheduled visit...
2017: PloS One
https://read.qxmd.com/read/28569182/a-pharmacogenetic-signature-of-high-response-to-copaxone-in-late-phase-clinical-trial-cohorts-of-multiple-sclerosis
#29
JOURNAL ARTICLE
Colin J Ross, Fadi Towfic, Jyoti Shankar, Daphna Laifenfeld, Mathis Thoma, Matthew Davis, Brian Weiner, Rebecca Kusko, Ben Zeskind, Volker Knappertz, Iris Grossman, Michael R Hayden
BACKGROUND: Copaxone is an efficacious and safe therapy that has demonstrated clinical benefit for over two decades in patients with relapsing forms of multiple sclerosis (MS). On an individual level, patients show variability in their response to Copaxone, with some achieving significantly higher response levels. The involvement of genes (e.g., HLA-DRB1*1501) with high inter-individual variability in Copaxone's mechanism of action (MoA) suggests the potential contribution of genetics to treatment response...
May 31, 2017: Genome Medicine
https://read.qxmd.com/read/28440858/treatment-with-disease-modifying-drugs-for-people-with-a-first-clinical-attack-suggestive-of-multiple-sclerosis
#30
REVIEW
Graziella Filippini, Cinzia Del Giovane, Marinella Clerico, Omid Beiki, Miriam Mattoscio, Federico Piazza, Sten Fredrikson, Irene Tramacere, Antonio Scalfari, Georgia Salanti
BACKGROUND: The treatment of multiple sclerosis has changed over the last 20 years. The advent of disease-modifying drugs in the mid-1990s heralded a period of rapid progress in the understanding and management of multiple sclerosis. With the support of magnetic resonance imaging early diagnosis is possible, enabling treatment initiation at the time of the first clinical attack. As most of the disease-modifying drugs are associated with adverse events, patients and clinicians need to weigh the benefit and safety of the various early treatment options before taking informed decisions...
April 25, 2017: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/28427690/factors-associated-with-adherence-to-disease-modifying-therapy-in-multiple-sclerosis-an-observational-survey-from-a-referral-center-in-lithuania
#31
JOURNAL ARTICLE
Neringa Duchovskiene, Dalia Mickeviciene, Giedre Jurkeviciene, Birute Dirziuviene, Renata Balnyte
AIM OF THE STUDY: To investigate adherence to disease modifying therapy (DMT) in Lithuanian population of multiple sclerosis patients and factors associated to it. METHODS: Patients receiving one of the following DMT's: Interferon β 1a (Rebif) 44 micrograms three times a week subdermally (s/c) or Interferon β 1a (Avonex) 30 micrograms weekly intramuscularly (i/m), or Interferon β 1b (Betaferon, Extavia) 250 micrograms once in two days s/c, or Glatiramer acetate (Copaxone) 20mg daily s/c, were presented with a questionnaire inquiring their demographic and clinical characteristics and adherence to treatment profile, as well as HAD scale and SF-36 questionnaire...
April 2017: Multiple Sclerosis and related Disorders
https://read.qxmd.com/read/28027680/comparative-effectiveness-of-interferons-in-relapsing-remitting-multiple-sclerosis-a-meta-analysis-of-real-world-studies
#32
COMPARATIVE STUDY
Thomas R Einarson, Basil G Bereza, Márcio Machado
BACKGROUND: Differences between interferons have been evaluated for over 20 years. While randomized controlled trial (RCT) data is mainly used for assessments and strong data for causal inferences, it does not necessarily reflect everyday practice. Real-world data may provide additional information. PURPOSE: To assess the results, quality, and representativeness of observational studies directly comparing interferons (IFNs) in RRMS. METHODS: Medline and Embase were searched for observational studies comparing IFN-beta-1a 30 mcg IM (Avonex 1 ), IFN-beta-1a 44 mcg SC (Rebif 2 ) and/or IFN-beta-1b 250 mcg SC (Betaseron 3 )...
March 2017: Current Medical Research and Opinion
https://read.qxmd.com/read/27970906/quality-of-life-in-relapsing-remmiting-multiple-sclerosis-influence-of-interferon-beta-1a-avonex-and-cinnovex-treatment
#33
JOURNAL ARTICLE
rS Shahtaheri, N Hatam
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://read.qxmd.com/read/27849348/reconsidering-the-economic-value-of-multiple-sclerosis-therapies
#34
JOURNAL ARTICLE
Tiffany Shih, Craig Wakeford, Dennis Meletiche, Jesse Sussell, Adrienne Chung, Yanmei Liu, Jin Joo Shim, Darius Lakdawalla
OBJECTIVES: To illustrate a more comprehensive view of value associated with medicines treating a highly severe illness and to apply these insights to estimate the costs and benefits of 3 treatments for multiple sclerosis (MS): Avonex, Tysabri, and Tecfidera. STUDY DESIGN: Retrospective study spanning 2002 to 2013. We used economic theory to derive the value of therapy to patients with MS and to individuals who face the risk of contracting MS in the future, under the alternative assumptions that therapies were fully insured or paid for out of pocket...
November 1, 2016: American Journal of Managed Care
https://read.qxmd.com/read/27828855/the-cross-reactivity-of-binding-antibodies-with-different-interferon-beta-formulations-used-as-disease-modifying-drugs-in-multiple-sclerosis-patients
#35
JOURNAL ARTICLE
Agnieszka Wencel-Warot, Slawomir Michalak, Marcin Warot, Alicja Kalinowska-Lyszczarz, Radoslaw Kazmierski
Interferon beta (IFNb) preparations are commonly used as first-line therapy in relapsing-remitting multiple sclerosis (RRMS). They are, however, characterized by limited efficacy, partly due to the formation of anti-IFNb antibodies in patients.In this pilot study, we assessed with the ELISA method the presence of the binding antibodies (BAbs) against interferon beta after 2 years of therapy with subcutaneous interferon beta 1a (Rebif) in 49 RRMS patients. Antibody levels were established again within 1 year after treatment withdrawal...
November 2016: Medicine (Baltimore)
https://read.qxmd.com/read/27798157/cd40-mediated-nf-%C3%AE%C2%BAb-activation-in-b-cells-is-increased-in-multiple-sclerosis-and-modulated-by-therapeutics
#36
JOURNAL ARTICLE
Ding Chen, Sara J Ireland, Gina Remington, Enrique Alvarez, Michael K Racke, Benjamin Greenberg, Elliot M Frohman, Nancy L Monson
CD40 interacts with CD40L and plays an essential role in immune regulation and homeostasis. Recent research findings, however, support a pathogenic role of CD40 in a number of autoimmune diseases. We previously showed that memory B cells from relapsing-remitting multiple sclerosis (RRMS) patients exhibited enhanced proliferation with CD40 stimulation compared with healthy donors. In this study, we used a multiparameter phosflow approach to analyze the phosphorylation status of NF-κB and three major MAPKs (P38, ERK, and JNK), the essential components of signaling pathways downstream of CD40 engagement in B cells from MS patients...
December 1, 2016: Journal of Immunology
https://read.qxmd.com/read/27512709/quality-of-life-in-relapsing-remitting-multiple-sclerosis-patients-receiving-cinnovex-compared-with-avonex
#37
JOURNAL ARTICLE
Nahid Hatam, Peivand Bastani, Rahil Sadat Shahtaheri
OBJECTIVE: There is an increasing recognition among clinicians and researchers that the impact of chronic illnesses and their treatments must be assessed in terms of their quality of life (QoL) in addition to more traditional measures of clinical outcomes. The aim of this study was to compare the QoL in patients with relapsing-remitting multiple sclerosis (RRMS) using Avonex or CinnoVex. METHODS: We conducted a cross-sectional study on one hundred patients with RRMS, fifty and fifty patients were being treated with Avonex (Biogen Idec, USA) and CinnoVex (CinnaGen, Iran), respectively...
July 2016: Journal of Research in Pharmacy Practice
https://read.qxmd.com/read/27306062/assessment-of-interleukin-17a-interleukin-10-and-transforming-growth-factor-beta1-serum-titers-in-relapsing-remitting-multiple-sclerosis-patients-treated-with-avonex-possible-biomarkers-for-treatment-response
#38
JOURNAL ARTICLE
Rodica Balasa, Smaranda Maier, Septimiu Voidazan, Adina Hutanu, Zoltan Bajko, Anca Motataianu, Brandusa Tilea, Cristina Tiu
INTRODUCTION: Individual response to interferon beta (IFN-β) 1a treatment is heterogeneous in multiple sclerosis (MS). Our objective was to find a connection between serum levels of interleukin (IL)-10, IL-17 and transforming growth factor beta (TGF-β)1 in MS patients treated with IFN-β in order to identify the nonresponders (NR). MATERIAL AND METHODS: We included in the study 32 healthy subjects and 32 MS patients: 10 naive, 10 early treated and 12 late treated with INF-β1a...
2017: CNS & Neurological Disorders Drug Targets
https://read.qxmd.com/read/27053635/combining-clinical-and-magnetic-resonance-imaging-markers-enhances-prediction-of-12-year-disability-in-multiple-sclerosis
#39
JOURNAL ARTICLE
Tomas Uher, Manuela Vaneckova, Lukas Sobisek, Michaela Tyblova, Zdenek Seidl, Jan Krasensky, Deepa Ramasamy, Robert Zivadinov, Eva Havrdova, Tomas Kalincik, Dana Horakova
BACKGROUND: Disease progression and treatment efficacy vary among individuals with multiple sclerosis. Reliable predictors of individual disease outcomes are lacking. OBJECTIVE: To examine the accuracy of the early prediction of 12-year disability outcomes using clinical and magnetic resonance imaging (MRI) parameters. METHODS: A total of 177 patients from the original Avonex-Steroids-Azathioprine study were included. Participants underwent 3-month clinical follow-ups...
January 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://read.qxmd.com/read/27003945/the-edss-plus-an-improved-endpoint-for-disability-progression-in-secondary-progressive-multiple-sclerosis
#40
JOURNAL ARTICLE
Diego Cadavid, Jeffrey A Cohen, Mark S Freedman, Myla D Goldman, Hans-Peter Hartung, Eva Havrdova, Douglas Jeffery, Raj Kapoor, Aaron Miller, Finn Sellebjerg, Deborah Kinch, Sophia Lee, Shulian Shang, Daniel Mikol
BACKGROUND: The Expanded Disability Status Scale (EDSS) has wide scientific and regulatory precedent but limited ability to detect clinically relevant disability progression in secondary progressive multiple sclerosis (SPMS) patients, partly due to a lack of meaningful measurement of short-distance ambulatory and upper-extremity function. OBJECTIVE: To present a rationale for a composite endpoint adding the timed 25-foot walk (T25FW) and 9-Hole Peg Test (9HPT) to EDSS for SPMS disability progression assessment...
January 2017: Multiple Sclerosis: Clinical and Laboratory Research
keyword
keyword
19164
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.